Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
STOCKHOLM, April 25, 2024 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
First Quarter 2024
Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)
Haematology revenue increased 46 per cent at CER to SEK 4,075 M (2,815), reflecting growth in all medicines, mainly driven by strong sales of Doptelet® of SEK 756 M (475), sales of Vonjo® of SEK 320 M (?), and sales of Aspaveli®/Empaveli® of SEK 240 M (95)
Immunology revenue decreased 11 per cent at CER to SEK 1,908 M (2,151), mainly reflecting a significant drop in Synagis® sales to SEK 520 M (1,398), partly compensated by strong sales of Gamifant® of SEK 438 M (219), and royalty on Beyfortustm of SEK 318 M (?)
Revenue from medicines in the strategic portfolio more than doubled in the quarter, to SEK 2,193 M (794), driving the majority of the growth. The strategic portfolio grew by 177 per cent at CER and helped to further transform the company
The adjusted EBITA margin1,2 was 37 per cent (40), excluding items affecting comparability (IAC)2. EBITA was SEK 2,177 M (2,121), corresponding to a margin of 35 per cent (40). EBIT was SEK 1,313 M (1,495)
Earnings per share (EPS) before dilution was SEK 2.35 (3.44)3. Adjusted EPS before dilution1 was SEK 2.70 (3.44)3. Cash flow from operating activities was SEK 2,256 M (1,983)
Outlook 2024 - unchanged
Revenue is anticipated to grow by a high single-digit percentage at CER
The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue
1. Alternative Performance Measures (APMs).
2. Items affecting comparability (IAC).
3. Comparatives have been adjusted to consider the bonus issue element in the rights issue carried out in 2023.
The strategic portfolio includes Sobi's medicines Aspaveli/Empaveli, Doptelet excluding China, Gamifant, Vonjo and Zynlonta®, and royalty on Sanofi's sales on Altuviiiotm and Beyfortus.
Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at 16:00 CEST.
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.
To participate in the conference call, please use the following dial-in details:
Sweden: +46 8 5051 0031 United Kingdom: +44 207 107 06 13 United States: +1 631 570 56 13
For other countries, please find the details here.
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 25 April 2024 at 08:00 CEST.
Think Together, California's leading nonprofit provider of afterschool, expanded learning and school improvement programs, is proud to announce it has recognized Colton Joint Unified School District with its Champion of Change Award at the district's...
Experts Live Europe, a premier conference for IT professionals and technology enthusiasts, is thrilled to announce Samantha Alleyne as the keynote speaker for its upcoming event in Budapest. Taking place on September 23-25, 2024, the conference...
In the news release, Nomic Unveils Bitcoin Liquid Staking Token Powered by Babylon's Bitcoin Staking Protocol, issued 10-Apr-2024 by Nomic DAO Foundation over PR Newswire, we are advised by the company that the dateline should read "GEORGE TOWN,...
United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, will unveil its latest MRI technology, boasting incredible advancements across various fronts, as a Gold sponsor at this year's ISMRM meeting.
The...
Affiliated Dermatologists (AD) is providing notice of a recent data security incident. At this time, AD is not aware of any misuse of any personal information in connection with this incident.
What Happened?
On March 5, 2024, AD detected it was the...